AssayIndex

HJ-2605-A4196

Sermorelin · 10 mg declared · Hubei Jianxiang Bioscience Co., Ltd. · manufactured 23 May 2026

CHARACTERISED
Lot code
HJ-2605-A4196
Supplier
HJ — Hubei Jianxiang Bioscience Co., Ltd.
Compound
Sermorelin
Compound class
Growth-hormone axis peptides
Declared label claim
10mg
Manufacture date
23 May 2026
Index quarter
2026-Q2
Independent assays
9
Laboratories involved
Medutest, Kestrel, Janoshik, PeptideMeter, Nordanalyt
Provenance mix
Buyer-sourced ×1 · Supplier-supplied ×8
Section 1

Reproducibility across independent tests

Every report below is an observation of the same physical material. What they disagree about is measurement; what they agree about is the lot. The size of the disagreement is compared against what the contributing laboratories' own repeatability figures predict.

Independent assays 9
Median purity 99.08% n=9
Spread (max − min) 1.19pp n=9
Standard deviation 0.342pp n=9
97.497.898.398.799.199.6100.0This lot (HJ-2605-A4196)This lot (HJ-2605-A4196): Q1 98.93, median 99.08, Q3 99.21, n=9outlier 98.37n=9All SermorelinAll Sermorelin: Q1 98.39, median 98.94, Q3 99.22, n=96n=96 Purity (% area)
Figure 1. This lot's independent purity results against the whole Sermorelin record set in the index. The vertical line is the index acceptance specification for the growth-hormone axis peptides class, 98.0 % area. A narrow box on the top row against a wide box on the bottom row is the ideal reading: it means the disagreement between lots is much larger than the disagreement within this one.
Section 2

Member reports 9

Every report the index holds on this lot. Each is a page carrying its own chromatogram, mass spectrum, mass balance, provenance and caveats.

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-042358HJ-2605-A4196Medutest2026-Q299.205.83Supplier-supplied0PASS
AX-2026-042359HJ-2605-A4196Kestrel2026-Q299.375.63Supplier-supplied1MARGINAL
AX-2026-042360HJ-2605-A4196Janoshik2026-Q298.865.7390.6Supplier-supplied0PASS
AX-2026-042361HJ-2605-A4196Medutest2026-Q298.935.4389.8Supplier-supplied1MARGINAL
AX-2026-042362HJ-2605-A4196PeptideMeter2026-Q298.935.80Supplier-supplied0PASS
AX-2026-042363HJ-2605-A4196Nordanalyt2026-Q299.215.8996.9Supplier-supplied0PASS
AX-2026-042364HJ-2605-A4196Janoshik2026-Q298.375.9097.1Buyer-sourced1FAIL
AX-2026-042365HJ-2605-A4196Janoshik2026-Q299.565.6189.6Supplier-supplied1MARGINAL
AX-2026-042366HJ-2605-A4196Janoshik2026-Q299.085.25Supplier-supplied0PASS
Section 3

By laboratory

Where more than one laboratory assayed this lot, the difference between them is a paired observation of their relative bias — the same material, the same time window, different instruments. Those pairs are what the index's bias estimates are built from.

LaboratoryReportsPurity results (% area)MedianGradientPublished bias (pp)Bias-adjusted
Medutest299.20, 98.9399.0625min+0.0898.98
Kestrel199.3799.3715min+0.2499.13
Janoshik498.86, 98.37, 99.56, 99.0898.9730min+0.0098.97
PeptideMeter198.9398.9328min-0.0598.98
Nordanalyt199.2199.2135min+0.0299.19

This lot contributes 10 paired comparisons to the inter-lab analysis.

Section 4

The supplier's certificate for this lot

One number the supplier wrote, beside the median of the numbers other people measured on the same physical material. That comparison is only available because the index groups by lot.

FigureSupplier COAThis reportIndex note
Purity (% area)99.1399.20divergence +0.05 pp vs batch median
Total impurities (% area)0.870.80
Largest single impurity (% area)0.580.42
Water (%)4.55.83
Counter-ion (%)not stated4.79
Peptide content (%w/w)not statednot determined
Endotoxin (EU/mg)not stated0.18
Method stated on certificateYEScolumn, gradient and wavelength given
Section 5

Impurity fingerprint

The named impurities reported across this lot's assays, with how consistently each was seen. A fingerprint is what allows two lot numbers held by different companies to be identified as one bulk.

Named impurityReported inMedian % areaRange
aspartimide (−18 Da)9 / 90.420.05–0.85
des-Tyr1 (−163 Da)9 / 90.230.16–0.41
deamidated Asn8 (+1 Da)9 / 90.170.11–0.42
truncated (1-25)9 / 90.120.05–0.23
Section 7

What this rollup does not establish